Namodenoson — Interim data
Q2 2027
Interim analysis data expected in Q2 2027Source filing
CANF biotech catalysts & pipeline
CAN-FITE BIOPHARMA LTD · Data as of 2026-10-25
Upcoming catalysts
Piclidenoson — Interim data
Q2 2027
Interim analysis data expected in Q2 2027Source filing
Namodenoson — Conference presentation
Oct 23–Oct 27
Clinical results from Can-Fite's Phase 2a study of namodenoson in advanced pancreatic adenocarcinoma have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026.Source filing